Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Pipeline Monitor
Avastin scores ninth approval
Roche's Avastin scores its ninth approval across six cancer types while a once-weekly diabetes treatment and a triple COPD therapy are filed.
Debating Point
Biosimilars - a promise delayed by bureaucracy
It's a year since Pfizer's Inflectra was PBS listed but the promised biosimilar awareness initiative is nowhere to be seen.
Approvals Action
Samsung Bioepis continues to emerge in biosimilars
The emergence of Samsung Bioepis as an important sponsor of biosimilars in Australia has continued with the registration of Renflexis, a version of infliximab.